Betta Pharmaceuticals Co., Ltd.

Shenzhen Stock Exchange 300558.SZ

Betta Pharmaceuticals Co., Ltd. Free Cash Flow Yield on January 27, 2025: -0.78%

Betta Pharmaceuticals Co., Ltd. Free Cash Flow Yield is -0.78% on January 27, 2025, a 27.57% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Betta Pharmaceuticals Co., Ltd. 52-week high Free Cash Flow Yield is -0.76% on December 04, 2024, which is 2.68% above the current Free Cash Flow Yield.
Betta Pharmaceuticals Co., Ltd. 52-week low Free Cash Flow Yield is -1.45% on July 23, 2024, which is -84.67% below the current Free Cash Flow Yield.
Betta Pharmaceuticals Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is -1.07%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Shenzhen Stock Exchange: 300558.SZ

Betta Pharmaceuticals Co., Ltd.

CEO	Dr. Lieming Ding
IPO Date	Nov. 9, 2016
Location	China
Headquarters	No. 355, Xingzhong Road
Employees	1,961
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Composite Materials Drugstores & Retail Pharmacies

Description

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.

Key trends

Past 5 years